Moolec Science SA - Form 20-F Summary
Business Context and Reporting Period
Company: Moolec Science SA (Luxembourg)
Reporting Period: Fiscal year ended June 30, 2024
Business Overview: Moolec is a science-based ingredient company pioneering molecular farming technology to produce animal proteins and oils within plants. The company operates in the United States, Europe, and South America. Key products include GLASO™ (high GLA safflower oil) and TSP Valorasoy™ (textured soy proteins). The company is an emerging growth company and a foreign private issuer.
Key Financial Metrics (Year Ended June 30, 2024)
| Metric | 2024 (USD) | 2023 (USD) |
|---|---|---|
| Revenue | $5,625,124 | $905,049 |
| Cost of Sales | $(5,152,543) | $(1,048,354) |
| Gross Profit | $472,581 | $(143,305) |
| Net Loss | $(7,312,260) | $(51,788,880) |
| Cash and Cash Equivalents | $5,389,928 | $2,527,673 |
| Total Debt (Current + Non-Current) | $14,259,391 | $2,645,289 |
| Accumulated Deficit | $(65,935,383) | $(58,623,123) |
Note: The 2023 net loss included a one-time non-cash charge of $42.7 million for share-based payment costs related to the listing of shares.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 521.5% to $5.6 million, primarily driven by the full-year consolidation of the ValoraSoy acquisition (completed April 2023), which contributes textured soy protein sales.
- Net Loss Reduction: Net loss decreased significantly to $7.3 million from $51.8 million. The prior year was heavily impacted by the $42.7 million non-cash listing cost charge, which did not recur in 2024.
- Debt Expansion: Total financial debt increased to approximately $14.3 million, up from $2.6 million. This includes a $10.9 million convertible note issued to Insud (Invim Corporativo S.L.) and other borrowings.
- Operating Expenses: Administrative expenses rose 56.4% to $7.5 million due to amortization, equity incentives, and professional fees. R&D expenses increased 31.2% to $1.8 million.
Guidance, Outlook, and Risks
Outlook and Recent Developments:
- Product Pipeline: GLASO™ is at the product launch stage. Meat replacement products (Piggy Sooy™ and PEEA1) are transitioning from early development to advanced stages, having received USDA-APHIS Regulatory Status Reviews concluding they pose no greater plant pest risk than non-GMO counterparts.
- Strategic Agreements: Entered into a 3-year offtake agreement for GLASO™ delivery in 2025 and a collaboration with Bunge Argentina for safflower varieties.
- Liquidity: Management believes current liquidity is adequate for the next 12 months but anticipates a need for additional financing to fund R&D and commercialization.
Key Risks:
- Profitability: The company has a history of losses and an accumulated deficit of $65.9 million. There is no assurance it will achieve profitability.
- Regulatory & Market Acceptance: Success depends on regulatory approvals for GMO products and public acceptance of molecular farming technologies.
- Macroeconomic Conditions: Significant operations in Argentina expose the company to hyperinflation, currency devaluation, and political instability (e.g., recent government reforms).
- Listing Status: The company received a Nasdaq notification in September 2024 regarding failure to maintain the $1.00 minimum bid price requirement, with a compliance period until March 10, 2025.
- Convertible Notes: Outstanding notes to Insud and Bioceres may be converted into equity, causing dilution, or require cash repayment at maturity.
Investor Verification Checklist
- Nasdaq Compliance: Verify the company's progress in regaining compliance with the $1.00 minimum bid price requirement by March 10, 2025.
- Debt Maturity & Conversion: Review the terms of the $10.9 million Insud convertible note and the $6.6 million Bioceres convertible note, specifically the strike prices ($6.00) and maturity dates (2026), to assess dilution risk or cash repayment obligations.
- Argentina Exposure: Assess the impact of Argentina's hyperinflationary environment and recent political reforms (Decree 70/2023, Bases Law) on the ValoraSoy subsidiary's financial reporting and operations.
- Product Commercialization: Monitor the execution of the GLASO™ offtake agreement and the timeline for regulatory clearance of meat replacement products (Piggy Sooy™/PEEA1) in target markets.
- Cash Burn Rate: Evaluate the $9.3 million net cash used in operating activities against the $5.4 million cash balance to determine the runway before additional capital raising is required.